Biomanufacturing Resilience: Self-Reliance in Active Pharmaceutical Ingredients
Session video recording will be published here once held.
Executive Summary
Biotech researchers, formulation leaders, and bulk drug park developers examine India's path to eliminate imported active pharmaceutical ingredient (API) dependencies and build global biosimilar leadership.
Key Discussion Points
- 1Bulk drug mega-parks in Andhra Pradesh, Gujarat, and Himachal Pradesh are commissioning shared effluent and steam utilities.
- 2Domestic synthesis of key starting materials (KSMs) for fermentation-based antibiotics has reached commercial volumes.
- 3Bio-CDMO services are expanding into mRNA therapies, monoclonal antibodies, and peptide manufacturing.
Main Policy & Industry Recommendations
Accelerate environmental clearances for high-containment biotech fermentation units.
Establish a National Life Sciences Seed Capital Fund for clinical trial phase-1 drug discovery.
Strategic Industry Implications
Insulates affordable medicine production for Indian hospitals and guarantees uninterrupted essential generic supplies globally.
Session Transcript
Timestamped recordIndia is known as the pharmacy of the world. But for too long, the critical raw materials for those medicines came from a single external border. The Viksit Bharat roadmap requires us to manufacture our own basic chemical building blocks.
Dr. Deepa Natarajan
Director General
Indian Pharmaceutical Alliance
Dr. H. P. Reddy
VerifiedExecutive Director
Dr. Reddy's Laboratories Active Ingredients
Fermentation & Synthetic Chemistry
Pradeep Joshi
VerifiedCEO
Gujarat Bulk Drug Park Infrastructure Ltd
Common Utility Logistics
- ›Production Linked Incentive Scheme for Bulk Drugs (Tranche 2).
- ›National Policy on Research and Development in Pharma-MedTech.